Accessibility settings

This paper is in the following e-collection/theme issue:

Pilot studies (non-ehealth) (244) Respiratory Medicine (207) Methodological Innovations (59) Hygiene and Infection Prevention (433) Early Results from COVID-19 Studies (454)

Published on in Vol 10 (2026)

Preprints (earlier versions) of this paper are available at https://preprints.jmir.org/preprint/77315, first published .
Elderly patient in hospital bed with oxygen mask, medical staff attending

Lucinactant, a Synthetic Surfactant for the Treatment of Acute Respiratory Distress Syndrome Caused by COVID-19: Phase 1/2A Trial

Lucinactant, a Synthetic Surfactant for the Treatment of Acute Respiratory Distress Syndrome Caused by COVID-19: Phase 1/2A Trial

Authors of this article:

Yuh-Chin Huang1 Author Orcid Image ;   Peter Morris2 Author Orcid Image ;   Robert Owens3 Author Orcid Image ;   Carlos Guardia4 Author Orcid Image ;   Steven Keller5 Author Orcid Image ;   Waldo Belloso6 Author Orcid Image ;   Lawrence Weinstein4 Author Orcid Image ;   Phillip Simmons4 Author Orcid Image ;   Steven Simonson4 Author Orcid Image
Article Authors Cited by Tweetations Metrics

Altmetric

Altmetric discovers Social Media mentions. Click the ‘See more details’ link for a full report.

Dimensions

Dimensions discovers Citations. Click the ‘details’ link for a full report.

Metrics Since Publication

Download .csv
Daily | Monthly | Annually